News AbbVie and J&J claim new Imbruvica okay in US AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL) to be approved by the FDA, its tenth indication.
News Roche's Mabthera faces cut-price competition in EU Blockbuster likely to face cheap near-copy for first time.
News AbbVie's Venclyxto approved in Europe in CLL AbbVie blood cancer drug tipped to be a blockbuster.
News NICE rejects Roche drug in follicular lymphoma NICE uncertain over survival data for Gazyvaro and bendamustine.
News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face